{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:57:04Z","timestamp":1759334224525,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"DOI":"10.7759\/cureus.93553","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:50:39Z","timestamp":1759236639000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Need for a Consensus Guideline for the Management of Non-Muscle-Invasive Bladder Cancer: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Obinna","family":"Enemoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayowa","family":"Adefehinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quadri A","family":"Sanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hykmat A","family":"Ogunbadejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Brabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obichukwu","family":"Iwunna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen O","family":"Agboro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Chukwumah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiodun","family":"Akintayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry I","family":"Njeakor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gentle C","family":"Uwaoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-04949-8","article-title":"Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates","volume":"42","author":"W\u00e9ber A","year":"2024","unstructured":"W\u00e9ber A, Vignat J, Shah R, et al.. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024, 42:237. 10.1007\/s00345-024-04949-8","journal-title":"World J Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk M","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al.. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022, 81:75-94. 10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier S","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, et al.. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol. 2016, 69:60-9. 10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"key":"ref4","unstructured":"Treatments. (2025). Accessed. July 30, 2025: https:\/\/actionbladdercanceruk.org\/treatments\/."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2020.1788635","article-title":"Cystoscopic surveillance of patients with non-muscle-invasive bladder cancer revisited","volume":"54","author":"Malmstr\u00f6m PU","year":"2020","unstructured":"Malmstr\u00f6m PU. Cystoscopic surveillance of patients with non-muscle-invasive bladder cancer revisited. Scand J Urol. 2020, 54:364-6. 10.1080\/21681805.2020.1788635","journal-title":"Scand J Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69","article-title":"Scoping studies: advancing the methodology","volume":"5","author":"Levac D","year":"2010","unstructured":"Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010, 5:69. 10.1186\/1748-5908-5-69","journal-title":"Implement Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018, 169:467-73. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"ref8","unstructured":"Apply PCC. (2025). Accessed. July 30, 2025: https:\/\/guides.library.unisa.edu.au\/ScopingReviews\/ApplyPCC."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004-2013","volume":"5","author":"Bree KK","year":"2022","unstructured":"Bree KK, Shan Y, Hensley PJ, et al.. Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004-2013. JAMA Netw Open. 2022, 5:e223050. 10.1001\/jamanetworkopen.2022.3050","journal-title":"JAMA Netw Open"},{"key":"ref10","article-title":"Pharmacologic therapies for non-muscle invasive bladder cancer: current and future treatments","volume":"4","author":"Goldberg IP","year":"2022","unstructured":"Goldberg IP, Lichtbroun B, Singer EA, Ghodoussipour S. Pharmacologic therapies for non-muscle invasive bladder cancer: current and future treatments. Arch Pharmacol Ther. 2022, 4:13-22.","journal-title":"Arch Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein JM","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, et al.. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024, 211:533-8. 10.1097\/JU.0000000000003846","journal-title":"J Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.09.017","article-title":"Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure","volume":"39","author":"Hurle R","year":"2021","unstructured":"Hurle R, Contieri R, Casale P, et al.. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure. Urol Oncol. 2021, 39:195.e7-13. 10.1016\/j.urolonc.2020.09.017","journal-title":"Urol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175024","article-title":"Intravesical combination therapies for non-muscle invasive bladder cancer: recent advances and future directions","volume":"926","author":"Li Y","year":"2022","unstructured":"Li Y, Youssef SF, Buanz AB. Intravesical combination therapies for non-muscle invasive bladder cancer: recent advances and future directions. Eur J Pharmacol. 2022, 926:175024. 10.1016\/j.ejphar.2022.175024","journal-title":"Eur J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S341896","article-title":"Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR)","volume":"14","author":"Musat MG","year":"2022","unstructured":"Musat MG, Kwon CS, Masters E, Sikirica S, Pijush DB, Forsythe A. Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR). Clinicoecon Outcomes Res. 2022, 14:35-48. 10.2147\/CEOR.S341896","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Non-muscle-invasive bladder cancer: an overview of potential new treatment options","volume":"39","author":"Shore ND","year":"2021","unstructured":"Shore ND, Palou Redorta J, Robert G, et al.. Non-muscle-invasive bladder cancer: an overview of potential new treatment options. Urol Oncol. 2021, 39:642-63. 10.1016\/j.urolonc.2021.05.015","journal-title":"Urol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211039052","article-title":"Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma","volume":"13","author":"Yassaie O","year":"2021","unstructured":"Yassaie O, Chehroudi C, Black PC. Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma. Ther Adv Med Oncol. 2021, 13:17588359211039052. 10.1177\/17588359211039052","journal-title":"Ther Adv Med Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","volume":"27","author":"Lerner SP","year":"2008","unstructured":"Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2008, 27:155-9. 10.1016\/j.urolonc.2007.11.033","journal-title":"Urol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01091-1","article-title":"Approaches to non-muscle-invasive bladder cancer","volume":"23","author":"Slovacek H","year":"2021","unstructured":"Slovacek H, Zhuo J, Taylor JM. Approaches to non-muscle-invasive bladder cancer. Curr Oncol Rep. 2021, 23:105. 10.1007\/s11912-021-01091-1","journal-title":"Curr Oncol Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage","volume":"40","author":"Balasubramanian A","year":"2022","unstructured":"Balasubramanian A, Gunjur A, Weickhardt A, Papa N, Bolton D, Lawrentschuk N, Perera M. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. World J Urol. 2022, 40:1111-24. 10.1007\/s00345-021-03908-x","journal-title":"World J Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612596","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets","volume":"24","author":"Claps F","year":"2023","unstructured":"Claps F, Pavan N, Ongaro L, et al.. BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets. Int J Mol Sci. 2023, 24:12596. 10.3390\/ijms241612596","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-022-00406-y","article-title":"Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)","volume":"9","author":"Jin YH","year":"2022","unstructured":"Jin YH, Zeng XT, Liu TZ, et al.. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022, 9:44. 10.1186\/s40779-022-00406-y","journal-title":"Mil Med Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11523-9","article-title":"The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer","volume":"23","author":"Chen JX","year":"2023","unstructured":"Chen JX, Huang WT, Zhang QY, et al.. The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer. BMC Cancer. 2023, 23:1018. 10.1186\/s12885-023-11523-9","journal-title":"BMC Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6304-y","article-title":"Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations","volume":"19","author":"Zhang J","year":"2019","unstructured":"Zhang J, Wang Y, Weng H, et al.. Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations. BMC Cancer. 2019, 19:1054. 10.1186\/s12885-019-6304-y","journal-title":"BMC Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.7487","article-title":"Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - abridged version","volume":"15","author":"Bhindi B","year":"2021","unstructured":"Bhindi B, Kool R, Kulkarni GS, et al.. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - abridged version. Can Urol Assoc J. 2021, 15:230-9. 10.5489\/cuaj.7487","journal-title":"Can Urol Assoc J"},{"key":"ref25","article-title":"Pharmacologic therapies for non-muscle invasive bladder cancer: current and future treatments","volume":"4","author":"Goldberg IP","year":"2022","unstructured":"Goldberg IP, Lichtbroun B, Singer EA, Ghodoussipour S. Pharmacologic therapies for non-muscle invasive bladder cancer: current and future treatments. Arch Pharmacol Ther. 2022, 4:13-22.","journal-title":"Arch Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non-muscle-invasive bladder cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a multicenter young academic urologists urothelial working group collaboration","volume":"7","author":"Soria F","year":"2024","unstructured":"Soria F, Rosazza M, Livoti S, et al.. Clinical validation of the intermediate-risk non-muscle-invasive bladder cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a multicenter young academic urologists urothelial working group collaboration. Eur Urol Oncol. 2024, 7:1497-503. 10.1016\/j.euo.2024.06.004","journal-title":"Eur Urol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.777","article-title":"Update on the management of non-muscle invasive bladder cancer","volume":"4","author":"Aldousari S","year":"2010","unstructured":"Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010, 4:56-64. 10.5489\/cuaj.777","journal-title":"Can Urol Assoc J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update","volume":"9","author":"Guallar-Garrido S","year":"2020","unstructured":"Guallar-Garrido S, Juli\u00e1n E. Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update. Immunotargets Ther. 2020, 9:1-11. 10.2147\/ITT.S202006","journal-title":"Immunotargets Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree IM","year":"2022","unstructured":"McElree IM, Steinberg RL, Martin AC, et al.. Sequential intravesical gemcitabine and docetaxel for Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer. J Urol. 2022, 208:589-99. 10.1097\/JU.0000000000002740","journal-title":"J Urol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2020.08.003","article-title":"Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)","volume":"45","author":"\u00c1lvarez-Maestro M","year":"2021","unstructured":"\u00c1lvarez-Maestro M, Guerrero-Ramos F, Rodr\u00edguez-Faba O, Dom\u00ednguez-Escrig JL, Fern\u00e1ndez-G\u00f3mez JM. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). Actas Urol Esp (Engl Ed). 2021, 45:93-102. 10.1016\/j.acuro.2020.08.003","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.009","article-title":"Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy","volume":"40","author":"Kukreja JB","year":"2022","unstructured":"Kukreja JB, Schroeck FR, Lotan Y, et al.. Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. Urol Oncol. 2022, 40:9.e19-27. 10.1016\/j.urolonc.2021.05.009","journal-title":"Urol Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2016.05.001","article-title":"Narrow band imaging for bladder cancer","volume":"3","author":"Hsueh TY","year":"2016","unstructured":"Hsueh TY, Chiu AW. Narrow band imaging for bladder cancer. Asian J Urol. 2016, 3:126-9. 10.1016\/j.ajur.2016.05.001","journal-title":"Asian J Urol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/CU9.0000000000000142","article-title":"The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer","volume":"16","author":"Cahill EM","year":"2022","unstructured":"Cahill EM, Chua K, Doppalapudi SK, Ghodoussipour S. The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer. Curr Urol. 2022, 16:121-6. 10.1097\/CU9.0000000000000142","journal-title":"Curr Urol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4103\/fjs.fjs_133_18","article-title":"Blue-light cystoscopy and narrow-band imaging in bladder cancer management","volume":"52","author":"Zang Z","year":"2019","unstructured":"Zang Z, Wu Q, Chiong E. Blue-light cystoscopy and narrow-band imaging in bladder cancer management. Formos J Surg. 2019, 52:155-60. 10.4103\/fjs.fjs_133_18","journal-title":"Formos J Surg"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2025.5724","article-title":"Unleashing the power of urine\u2011based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (review)","volume":"66","author":"Wan X","year":"2025","unstructured":"Wan X, Wang D, Zhang X, Xu M, Huang Y, Qin W, Chen S. Unleashing the power of urine\u2011based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (review). Int J Oncol. 2025, 66:18. 10.3892\/ijo.2025.5724","journal-title":"Int J Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/CU9.0000000000000072","article-title":"Treatment and disease management patterns for Bacillus Calmette-Gu\u00e9rin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: a real-world data analysis","volume":"16","author":"Broughton EI","year":"2022","unstructured":"Broughton EI, Chun DS, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G. Treatment and disease management patterns for Bacillus Calmette-Gu\u00e9rin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: a real-world data analysis. Curr Urol. 2022, 16:147-53. 10.1097\/CU9.0000000000000072","journal-title":"Curr Urol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-230083","article-title":"The evolution of nadofaragene firadenovec: a review and the path forward","volume":"10","author":"Steinmetz AR","year":"2024","unstructured":"Steinmetz AR, Mokkapati S, McConkey D, Dinney CP. The evolution of nadofaragene firadenovec: a review and the path forward. Bladder Cancer. 2024, 10:105-12. 10.3233\/BLC-230083","journal-title":"Bladder Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388273-exploring-the-need-for-a-consensus-guideline-for-the-management-of-non-muscle-invasive-bladder-cancer-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:50:40Z","timestamp":1759236640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388273-exploring-the-need-for-a-consensus-guideline-for-the-management-of-non-muscle-invasive-bladder-cancer-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.93553","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}